Keyword: Dupixent

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Some Big Pharma CEOs got big pay raises last year despite problems at their companies. Sanofi chief Olivier Brandicourt wasn't one of them.

Dupixent is now the first FDA-approved biologic for adolescents with eczema—and it's on the priority review track for adult sinusitis, too.

After a strong fourth quarter, Sanofi expects further growth in 2019.

England's cost watchdog has removed a previous restriction on AZ's Fasenra, allowing it to be funded for an expanded pool of patients.

A lot has changed in the severe asthma market lately—including the way GlaxoSmithKline is talking about its contender, Nucala.

The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

Strong data for Dupixent in sinusitis could boost sales for Sanofi and Regeneron, but challenges abound, including payer pushback.